Amifostine and curative intent chemoradiation for compromised cancer patients

Nam P. Nguyen, Barry Levinson, Suresh Dutta, Ulf Karlsson, Kevin C. Kelly, Jonathan Dowell, Adir Ludin, Sabah Sallah

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Concurrent chemotherapy and radiation are usually indicated for locally advanced carcinomas such as head and neck and anal malignancies. Because of the toxicity of the treatment, patient selection plays an important role in recommendations to treat with a curative intent. Elderly patients (>70 years), those with underlying medical conditions or acquired immunological disorders (AIDS) are commonly excluded from combined modality therapy because of their perceived inability to tolerate the aggressive treatment. They may thus be deprived of a potentially curative therapy. In an attempt to improve outcome, we conducted a pilot study using amifostine, a radioprotector, to increase the tolerance of such compromised individuals to treatment. Amifostine (500 mg intravenously) was given during chemotherapy on days 1-5, and days 21-25 of radiation regimen. All patients were able to complete the chemoradiation. Despite the locally advanced stage of the disease, five out of our six patients achieved a complete response (CR). One patient with synchronous primaries had a complete response for the base of tongue cancer and regression of the esophageal cancer, which allowed him to resume oral feeding. All patients achieved improved quality of life. Successful chemoradiation appears to be feasible in patients with advanced stage, age and/or underlying medical conditions when amifostine is integrated in the treatment.

Original languageEnglish (US)
Pages (from-to)1649-1656
Number of pages8
JournalAnticancer Research
Volume23
Issue number2 C
StatePublished - Mar 2003

Fingerprint

Amifostine
Neoplasms
Radiation
Tongue Neoplasms
Therapeutics
Drug Therapy
Combined Modality Therapy
Esophageal Neoplasms
Patient Selection
Neck
Head
Quality of Life
Carcinoma

Keywords

  • Amifostine
  • Chemoradiation
  • Compromised

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Nguyen, N. P., Levinson, B., Dutta, S., Karlsson, U., Kelly, K. C., Dowell, J., ... Sallah, S. (2003). Amifostine and curative intent chemoradiation for compromised cancer patients. Anticancer Research, 23(2 C), 1649-1656.

Amifostine and curative intent chemoradiation for compromised cancer patients. / Nguyen, Nam P.; Levinson, Barry; Dutta, Suresh; Karlsson, Ulf; Kelly, Kevin C.; Dowell, Jonathan; Ludin, Adir; Sallah, Sabah.

In: Anticancer Research, Vol. 23, No. 2 C, 03.2003, p. 1649-1656.

Research output: Contribution to journalArticle

Nguyen, NP, Levinson, B, Dutta, S, Karlsson, U, Kelly, KC, Dowell, J, Ludin, A & Sallah, S 2003, 'Amifostine and curative intent chemoradiation for compromised cancer patients', Anticancer Research, vol. 23, no. 2 C, pp. 1649-1656.
Nguyen NP, Levinson B, Dutta S, Karlsson U, Kelly KC, Dowell J et al. Amifostine and curative intent chemoradiation for compromised cancer patients. Anticancer Research. 2003 Mar;23(2 C):1649-1656.
Nguyen, Nam P. ; Levinson, Barry ; Dutta, Suresh ; Karlsson, Ulf ; Kelly, Kevin C. ; Dowell, Jonathan ; Ludin, Adir ; Sallah, Sabah. / Amifostine and curative intent chemoradiation for compromised cancer patients. In: Anticancer Research. 2003 ; Vol. 23, No. 2 C. pp. 1649-1656.
@article{ef387ff2ca8f4889b4ad67c9ee7c1bb3,
title = "Amifostine and curative intent chemoradiation for compromised cancer patients",
abstract = "Concurrent chemotherapy and radiation are usually indicated for locally advanced carcinomas such as head and neck and anal malignancies. Because of the toxicity of the treatment, patient selection plays an important role in recommendations to treat with a curative intent. Elderly patients (>70 years), those with underlying medical conditions or acquired immunological disorders (AIDS) are commonly excluded from combined modality therapy because of their perceived inability to tolerate the aggressive treatment. They may thus be deprived of a potentially curative therapy. In an attempt to improve outcome, we conducted a pilot study using amifostine, a radioprotector, to increase the tolerance of such compromised individuals to treatment. Amifostine (500 mg intravenously) was given during chemotherapy on days 1-5, and days 21-25 of radiation regimen. All patients were able to complete the chemoradiation. Despite the locally advanced stage of the disease, five out of our six patients achieved a complete response (CR). One patient with synchronous primaries had a complete response for the base of tongue cancer and regression of the esophageal cancer, which allowed him to resume oral feeding. All patients achieved improved quality of life. Successful chemoradiation appears to be feasible in patients with advanced stage, age and/or underlying medical conditions when amifostine is integrated in the treatment.",
keywords = "Amifostine, Chemoradiation, Compromised",
author = "Nguyen, {Nam P.} and Barry Levinson and Suresh Dutta and Ulf Karlsson and Kelly, {Kevin C.} and Jonathan Dowell and Adir Ludin and Sabah Sallah",
year = "2003",
month = "3",
language = "English (US)",
volume = "23",
pages = "1649--1656",
journal = "Anticancer Research",
issn = "0250-7005",
publisher = "International Institute of Anticancer Research",
number = "2 C",

}

TY - JOUR

T1 - Amifostine and curative intent chemoradiation for compromised cancer patients

AU - Nguyen, Nam P.

AU - Levinson, Barry

AU - Dutta, Suresh

AU - Karlsson, Ulf

AU - Kelly, Kevin C.

AU - Dowell, Jonathan

AU - Ludin, Adir

AU - Sallah, Sabah

PY - 2003/3

Y1 - 2003/3

N2 - Concurrent chemotherapy and radiation are usually indicated for locally advanced carcinomas such as head and neck and anal malignancies. Because of the toxicity of the treatment, patient selection plays an important role in recommendations to treat with a curative intent. Elderly patients (>70 years), those with underlying medical conditions or acquired immunological disorders (AIDS) are commonly excluded from combined modality therapy because of their perceived inability to tolerate the aggressive treatment. They may thus be deprived of a potentially curative therapy. In an attempt to improve outcome, we conducted a pilot study using amifostine, a radioprotector, to increase the tolerance of such compromised individuals to treatment. Amifostine (500 mg intravenously) was given during chemotherapy on days 1-5, and days 21-25 of radiation regimen. All patients were able to complete the chemoradiation. Despite the locally advanced stage of the disease, five out of our six patients achieved a complete response (CR). One patient with synchronous primaries had a complete response for the base of tongue cancer and regression of the esophageal cancer, which allowed him to resume oral feeding. All patients achieved improved quality of life. Successful chemoradiation appears to be feasible in patients with advanced stage, age and/or underlying medical conditions when amifostine is integrated in the treatment.

AB - Concurrent chemotherapy and radiation are usually indicated for locally advanced carcinomas such as head and neck and anal malignancies. Because of the toxicity of the treatment, patient selection plays an important role in recommendations to treat with a curative intent. Elderly patients (>70 years), those with underlying medical conditions or acquired immunological disorders (AIDS) are commonly excluded from combined modality therapy because of their perceived inability to tolerate the aggressive treatment. They may thus be deprived of a potentially curative therapy. In an attempt to improve outcome, we conducted a pilot study using amifostine, a radioprotector, to increase the tolerance of such compromised individuals to treatment. Amifostine (500 mg intravenously) was given during chemotherapy on days 1-5, and days 21-25 of radiation regimen. All patients were able to complete the chemoradiation. Despite the locally advanced stage of the disease, five out of our six patients achieved a complete response (CR). One patient with synchronous primaries had a complete response for the base of tongue cancer and regression of the esophageal cancer, which allowed him to resume oral feeding. All patients achieved improved quality of life. Successful chemoradiation appears to be feasible in patients with advanced stage, age and/or underlying medical conditions when amifostine is integrated in the treatment.

KW - Amifostine

KW - Chemoradiation

KW - Compromised

UR - http://www.scopus.com/inward/record.url?scp=0038539335&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0038539335&partnerID=8YFLogxK

M3 - Article

C2 - 12820436

AN - SCOPUS:0038539335

VL - 23

SP - 1649

EP - 1656

JO - Anticancer Research

JF - Anticancer Research

SN - 0250-7005

IS - 2 C

ER -